Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine
Issue link: https://clinicalomics.epubxp.com/i/853204
www.clinicalomics.com July/August 2017 Clinical OMICs 7 Thermo Fisher Scientific has introduced a new liquid chromatography-tandem mass spectrometry (LC-MS/MS) platform aimed at the clinical lab space, the Cascadion Clinical Analyzer. The tool was specifically designed to fit within the workflow and turnaround times associated with hospital labs combining ease of use, with the proven sensitivity of LC-MS/MS. According to Robert DeWitte, vice pres- ident and general manager of mass spec- trometry diagnostics at Thermo Fisher, Cascadion was developed over the course of the last six years to specifically meet the needs of hospital clinical labs, where quick sample-to-answer operation of clinical ana- lyzers requires only minimal training. "A hospital lab is a high-tech, mostly automated operating environment," DeWitte said. "But mass spec has often run in its own separate room within the lab and has required a Ph.D. and a couple of Master 's-level people. Four or five people focused on running these research oriented instruments to create a relatively small amount of data." The reason hospitals resorted to having LC-MS systems run, essentially, as a separate island within the clinical diagnostics lab was because for a handful of tests, the existing immunoassays available weren't accurate enough to give clinicians the specificity and selectivity they could get from mass spec. "In other words, they moved the gold-standard technology right into their lab," DeWitte noted. Until recently, this seemed like the only solution, albeit one that was not broadly accessible to many hospitals since the skill- set needed to run these systems were not what is found in a typical hospital setting. Thermo Fisher aims to change this para- digm with Cascadion. The system was com- pletely designed and built from the ground up using Thermo Fisher products and technologies and is designed to be used by laboratory staff with no specialized LC-MS knowledge or in-depth training. "Thermo Fisher is uniquely positioned to deliver an automated clinical analyzer that builds on our leading mass spectrom- etry platform," said Alan Sachs, M.D., Ph.D., CSO at Thermo Fisher Scientific. "It's designed to provide clinical laboratories with a solution that is both efficient and effective in providing results for some of the most sought after clinical tests. Cascadion has the potential to set new standards in the detection and measurement of specialty small molecule assays in the clinical lab." The automated system was also designed to be more on par with other clinical test- ing platforms that are standards-based for workflows and materials while allowing samples to be analyzed as they come into the lab. Current LC-MS use in the clinical lab is built around lab-developed tests, essentially each lab's homebrew, resulting in a lack of standard protocols from lab to lab. In addi- tion, its batch-directed workflows often have hospital labs running one batch per day on their mass spec platform—or even less frequently depending on their testing volume. "It is a totally disjointed workflow com- pared to what is happening in the rest of laboratory where every sample is stat and needs a short turnaround time," DeWitte added. "If you think about something done on an AutoAnalyzer, the lab is built around getting answers in 90 minutes or less." While DeWitte wouldn't detail specific turnaround times for Cascadion, he did say the platform is intended to provide the same kind of quick answers as other analytical tools found in a clinical lab. The platform is not currently available to new custom- ers as Thermo Fisher is working toward receiving EU marketing approval for 2018, and FDA 501(k) clearance sometime after its CE-IVD mark. Assays under development for Casca- dion include tests for vitamin D, testos- terone, and immunosuppressant drug monitoring.—Chris Anderson Sami Mäki-Rahkola / Thermo Fisher Scientific Thermo Fisher Takes Aim at Clinical Mass Spec Market